A high-tech device that can monitor medication use and compliance has been cleared by the FDA for use with AstraZeneca’s Airsupra and Breztri inhalers.
AstraZeneca easily delivered on chief executive Pascal Soriot’s pledge to deliver $45 billion in revenues by 2023, set a decade earlier as he fended off a takeover bid by
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.